WASHINGTON / RankWire.AI / – A groundbreaking study published in the journal Science reveals that scientists have pinpointed a rare inherited genetic mutation that can elevate an individual’s risk of developing lung cancer by approximately 25 times overall, and by about 60 times among those who have never smoked, according to findings from researchers at the Dana-Farber Cancer Institute and the 23andMe Research Institute. The investigation analyzed anonymized genetic information from over 3.3 million individuals, with the germline variant, known as EGFR T790M, emerging as one of the most potent inherited risk factors for lung cancer identified to date.

This mutation is situated in the epidermal growth factor receptor gene, which plays a key role in controlling cell growth and division within lung tissue. While somatic mutations in EGFR, acquired during a person’s lifetime, are well-established drivers of non-small cell lung cancer, the T790M germline variant is inherited from birth and found in every cell. Data from the National Cancer Institute indicates that roughly 1 in every 15,850 individuals in the United States carries this mutation. Lead author Dr. Jaclyn LoPiccolo pointed out that carriers of the variant face about a 62-fold increased risk of lung cancer among non-smokers, compared to an approximate 11-fold increase among those with a history of smoking.
Gene genealogy analysis uncovered that the EGFR T790M mutation is disproportionately prevalent in populations across Southern Appalachia, specifically in Tennessee and Alabama. Evolutionary geneticists traced the origin of this mutation to British and Irish settlers who migrated to North America during colonial times, with its frequency increasing following a genetic bottleneck around 200 years ago. Senior study author Dr. Pasi A. Jänne highlighted that, although lung cancer screening is predominantly based on tobacco exposure, recognizing significant genetic risk factors opens avenues for targeted low-dose computed tomography screening in non-smoking carriers.
Genetic Mutation May Amplify Lung Cancer Risk Up to 60 Times in Non-Smokers
Supported by the National Institutes of Health, preclinical and clinical trials confirmed that the mutation has a strong specific association with lung cancer, with no significant links to 17 other common cancers examined in the dataset. Oncologists emphasized that while tobacco use remains the primary cause of lung cancer, the growing incidence of non-smoking-related cases has made it a rising global health concern. Several pharmaceutical companies, such as AstraZeneca, are actively developing targeted tyrosine kinase inhibitors, including Tagrisso, to treat lung cancers with EGFR mutations when tumors progress.
Co-senior author Dr. Alexander Gusev pointed out that the research demonstrates how a single inherited point mutation can exert an exceptionally strong influence on disease susceptibility. Medical professionals advise that individuals with multiple relatives affected by lung cancer, unexplained multifocal lung nodules, or ancestral ties to Southern Appalachia seek guidance from genetic counselors. The researchers stress that possessing the mutation does not ensure a lung cancer diagnosis, as environmental factors and secondary genetic changes also play a role in whether malignant transformation occurs over a lifetime.
Multicenter Study Analyzes Genetic Data from Over Three Million Participants
The research alliance aims to broaden observational efforts through the ongoing INHERIT Study, focusing on additional inherited EGFR variants across diverse racial populations. Longitudinal studies will seek to identify specific environmental triggers and secondary genetic alterations that determine why some carriers develop tumors while others remain unaffected.
Comprehensive data on population genetics, risk assessments, and screening guidelines are available via peer-reviewed medical repositories and institutional release portals. Presentations of updated biomarker findings are scheduled at upcoming international oncology conferences to shape future screening strategies.
}**q986g4cdxhf**
